SARS-COV-2-SPECIFIC T CELLS
Embodiments of the disclosure includes methods of producing viral-specific therapy (VST) cells specific for the SARS-CoV-2 virus and uses of the cells. The methods may utilized peptide mixtures and stimulation of mononuclear cells using particular cytokine cocktails. The cells may also be genetically modified to lack expression of one or more endogenous genes, including one or more genes that renders the cells more effective and/or able to withstand deleterious conditions, such as the presence of glucocorticoids..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 18. Nov. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
REZVANI KATY [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-11-18, Last update posted on www.tib.eu: 2024-03-04, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
CA3181774 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016604377 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016604377 | ||
| 003 | DE-627 | ||
| 005 | 20240308100812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016604377 | ||
| 035 | |a (EPA)CA3181774 | ||
| 035 | |a (EPA)78525168 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a REZVANI KATY |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-COV-2-SPECIFIC T CELLS |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-11-18, Last update posted on www.tib.eu: 2024-03-04, Last updated: 2024-03-08 | ||
| 520 | |a Embodiments of the disclosure includes methods of producing viral-specific therapy (VST) cells specific for the SARS-CoV-2 virus and uses of the cells. The methods may utilized peptide mixtures and stimulation of mononuclear cells using particular cytokine cocktails. The cells may also be genetically modified to lack expression of one or more endogenous genes, including one or more genes that renders the cells more effective and/or able to withstand deleterious conditions, such as the presence of glucocorticoids. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHPALL ELIZABETH |4 aut | |
| 700 | 0 | |a BASAR RAFET |4 aut | |
| 700 | 0 | |a MARIN COSTA DAVID |4 aut | |
| 700 | 0 | |a UPRETY NADIMA |4 aut | |
| 700 | 0 | |a ENSLEY EMILY |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 18. Nov. |
| 773 | 1 | 8 | |g year:2021 |g day:18 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78525168/publication/CA3181774A1?q=CA3181774 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 18 |c 11 | ||